Most Read Articles
Stephen Padilla, 13 Oct 2020
Tocilizumab is a common treatment for rheumatoid arthritis (RA) patients with comorbid conditions or obesity and is effective irrespective of comorbidity burden or obesity status, according to a study.
Pearl Toh, 08 Jul 2020
The investigational JAK1* inhibitor filgotinib was noninferior to adalimumab in reducing disease activity in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response to methotrexate (MTX-IR), according to the FINCH 1 study presented at EULAR 2020 Virtual Meeting.
17 Nov 2020
Treatment with E6011, a novel cell trafficking inhibitor targeting the fractalkine (FKN)‐CX3CR1 interaction, confers modest benefits in rheumatoid arthritis (RA), according to the results of a phase II trial.
15 Jul 2020
New drug applications approved by US FDA as of 01 - 15 July 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Product Highlight - Vyzulta

16 Sep 2020
Breakthrough in Glaucoma Treatment Over 20 Years.

One Molecule, Two Outflow Pathways.

- Lowers IOP by increasing outflow through both the trabecular meshwork and uveoscleral pathway1
- Greater mean diurnal IOP reduction from baseline vs Latanoprost 0.005%2
- Superior IOP reduction vs Timolol 0.5% at all tested time points3
- Demonstrated safety profile3,4


Please refer to full package insert for the details.

References:
1. Cavet ME, DeCory HH. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies. J Ocul Pharmacol Ther 2018; 34(1-2): 52-60.
2. Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 2015; 99(6): 738-45.
3. Weinreb RN, Liebmann JM, Martin KR, et al. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. J Glaucoma 2018; 27(1): 7-15.
4. VYZULTA® Hong Kong prescribing information [version: 06/2018].


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 13 Oct 2020
Tocilizumab is a common treatment for rheumatoid arthritis (RA) patients with comorbid conditions or obesity and is effective irrespective of comorbidity burden or obesity status, according to a study.
Pearl Toh, 08 Jul 2020
The investigational JAK1* inhibitor filgotinib was noninferior to adalimumab in reducing disease activity in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response to methotrexate (MTX-IR), according to the FINCH 1 study presented at EULAR 2020 Virtual Meeting.
17 Nov 2020
Treatment with E6011, a novel cell trafficking inhibitor targeting the fractalkine (FKN)‐CX3CR1 interaction, confers modest benefits in rheumatoid arthritis (RA), according to the results of a phase II trial.
15 Jul 2020
New drug applications approved by US FDA as of 01 - 15 July 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.